Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment

Rhythm Pharmaceuticals ((RYTM)) announced an update on their ongoing clinical study.

Rhythm Pharmaceuticals is conducting a study titled A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Hypothalamic Obesity (HO). The study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of RM-718 in both healthy individuals with obesity and patients with hypothalamic obesity. This research is significant as it explores potential treatments for obesity-related conditions, which are prevalent and challenging to manage.

The intervention being tested is RM-718, a drug administered via subcutaneous injection. It is designed to be given in single or multiple ascending doses, depending on the study part, to assess its effects and safety profile.

The study is interventional, with a randomized and parallel assignment model. It employs triple masking, meaning that participants, care providers, and investigators are unaware of who receives the drug versus a placebo. The primary purpose of the study is treatment-focused, aiming to find effective interventions for obesity-related conditions.

The study began on March 5, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

From a market perspective, this study could significantly impact Rhythm Pharmaceuticals’ stock performance and investor sentiment. Positive results could enhance the company’s market position, especially in the competitive obesity treatment sector. Investors should watch for updates as they could influence market dynamics.

The study is currently recruiting, with further details available on the ClinicalTrials portal.